04/06/2024 Calcitonin gene-related peptide (CGRP) monoclonal antibodies for prophylaxis of migraine
The Ministry of Health’s Drug Advisory Committee has recommended:
Galcanezumab 120 mg/mL solution for injection in pre-filled pen for prophylaxis of migraine in adults who have at least four migraine days a month prior to commencement of treatment with galcanezumab. Patients must have experienced an inadequate response, intolerance, or a contraindication to at least three migraine prophylactic medications. Treatment with galcanezumab should be stopped after 12 weeks if:
a) in episodic migraine, the number of migraine days per month does not reduce by at least 50% compared with baseline;
b) in chronic migraine, the number of migraine days per month does not reduce by at least 30% compared with baseline.
Funding status
RGalcanezumab 120 mg/mL solution for injection in pre-filled pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.
NRMAF assistance does not apply to galcanezumab 100 mg/mL solution for injection in pre-filled syringe, or any formulations or strengths of eptinezumab, erenumab or fremanezumab.